Increased prevalence of hyperparathyroidism (HP) has been observed in primary aldosteronism (PA) patients. However, HP prevalence in milder forms of PA has not to date been evaluated.
The objectives of this study were to assess the prevalence of primary and secondary HP in overt and milder misdiagnosed cases of PA and to investigate the effect of treatment on parathormone (PTH) secretion.
Patients and methods
Seventy PA patients with normal renal function were included prospectively. Specifically, patients with biochemically overt PA (increased basal aldosterone/renin ratio (ARR) and a positive diagnostic suppression test (DCVT)) and patients with mild PA (normal basal ARR and a positive DCVT) were analyzed. Mean blood pressure and mineral metabolism were evaluated at diagnosis and after treatment.
Primary and secondary HP were found in 4.3% (3/70) and 51.4% (36/70) of patients, respectively, and biochemically overt and mild PA in 47.1% (33/70) and 52.9% (37/70) of patients, respectively. Sixty-three PA patients were followed up after treatment without receiving calcium or vitamin D. There was a decrease of mean blood pressure (p < 0.001), PTH (p < 0.001), and 24-h urinary calcium (p < 0.001), and an increase of serum potassium (p < 0.001) and calcium (p = 0.018) levels in secondary HP patients. There was no significant difference between biochemically overt and mild PA patients as concerned serum PTH, calcium, and 25-hydroxyvitamin-D levels either before or after treatment. Aldosterone levels before treatment were positively correlated with serum PTH levels.
HP prevalence was high in both overt and mild PA patients, whereas the effect of treatment on serum and urinary calcium and PTH levels was similar in both groups.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Rossi GP et al (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48(11):2293–2300. https://doi.org/10.1016/j.jacc.2006.07.059
Vasan RS et al (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351(1):33–41. https://doi.org/10.1056/nejmoa033263
Brown JM et al (2017) The spectrum of subclinical primary aldosteronism and incident hypertension. Ann Intern Med 167(9):630. https://doi.org/10.7326/M17-0882
Williams B, Brown MJ (2018) Investigation of primary aldosteronism in patients with resistant hypertension – authors’ reply. Lancet Diabetes Endocrinol 6(8):600–601. https://doi.org/10.1016/S2213-8587(18)30174-8
Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G (2015) Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol 172(5):R191-203. https://doi.org/10.1530/EJE-14-0537
Brown JM et al (2020) The unrecognized prevalence of primary aldosteronism. Ann Intern Med 173(1):10–20. https://doi.org/10.7326/M20-0065
Tsiavos V et al (2016) A new highly sensitive and specific overnight combined screening and diagnostic test for primary aldosteronism. Eur J Endocrinol 175(1):21–28. https://doi.org/10.1530/EJE-16-0003
Tomaschitz A et al (2012) Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res 94(1):10–19. https://doi.org/10.1093/cvr/cvs092
Asbach E, Bekeran M, Reincke M (2015) Parathyroid gland function in primary aldosteronism. Horm Metab Res 47(13):994–999. https://doi.org/10.1055/s-0035-1565224
Rossi GP et al (2012) Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 60(2):431–436. https://doi.org/10.1161/HYPERTENSIONAHA.112.195891
Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H (1991) Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. https://doi.org/10.1210/endo-129-1-489
Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG (2001) PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Metab 280(2):E209–E213. https://doi.org/10.1152/ajpendo.2001.280.2.E209
Rosenberg J, Pines M, Hurwitz S (1987) Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol 112(3):431–437. https://doi.org/10.1677/joe.0.1120431
Pilz S, Tomaschitz A, März W, Cavalier E, Ritz E (2010) Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int 87(4):373–374. https://doi.org/10.1007/s00223-010-9409-5
Asbach E et al (2020) Primary and secondary hyperparathyroidism in patients with primary aldosteronism – findings from the German Conn’s Registry. Exp Clin Endocrinol Diabetes 128(04):246–254. https://doi.org/10.1055/a-1027-6472
Rossi G (1995) Diagnosis and treatment of primary aldosteronism. Ann Intern Med 123(1):73. https://doi.org/10.7326/0003-4819-123-1-199507010-00013
Maniero C et al (2012) Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens. https://doi.org/10.1097/HJH.0b013e32834f0451
Pilz S et al (2012) Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 97(1):E75–E79. https://doi.org/10.1210/jc.2011-2183
Schiffl H, Lang SM (2011) Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol 2011:1–6. https://doi.org/10.1155/2011/974647
Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S (2017) Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 177(6):R297–R308. https://doi.org/10.1530/EJE-17-0485
Tomaschitz A et al (2014) Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 63(1):20–31. https://doi.org/10.1016/j.metabol.2013.08.016
Kovacs L, Goth M, Szabolcs I, Dohan O, Ferencz A, Szilagyi G (1998) The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 138(5):543–547. https://doi.org/10.1530/eje.0.1380543
Vaidya A, Carey RM (2020) Evolution of the primary aldosteronism syndrome: updating the approach. J Clin Endocrinol Metab 105(12):3771–3783. https://doi.org/10.1210/clinem/dgaa606
Williams TA, Reincke M (2018) Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol 179(1):R19–R29. https://doi.org/10.1530/EJE-17-0990
Funder JW et al (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(5):1889–1916. https://doi.org/10.1210/jc.2015-4061
Levey AS et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Chen G et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100(6):2420–2424. https://doi.org/10.1210/jc.2014-4432
Brunaud L et al (2009) Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 146(6):1035–1041. https://doi.org/10.1016/j.surg.2009.09.041
Fertig A, Webley M, Lynn JA (1980) Primary hyperparathyroidism in a patient with Conn’s syndrome. Postgrad Med J 56(651):45–47. https://doi.org/10.1136/pgmj.56.651.45
A. Concistré et al., “Primary aldosteronism with concurrent primary hyperparathyroidism: clinical case load in a single centre.,” Eur. Rev. Med. Pharmacol. Sci., vol. 19, no. 6, pp. 971–6, 2015, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/25855921
Tomaschitz A et al (2016) Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial. J Hypertens 34(7):1347–1356. https://doi.org/10.1097/HJH.0000000000000927
A Vaidya, JS Williams (2012) “The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes,” Metabolism: Clinical and Experimental https://doi.org/10.1016/j.metabol.2011.09.007
NA Ismail, NA Kamaruddin, S Azhar Shah, N Sukor (2020) “The effect of vitamin D treatment on clinical and biochemical outcomes of primary aldosteronism,” Clin. Endocrinol. (Oxf), https://doi.org/10.1111/cen.14177
Brown JM, Vaidya A (2014) Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes 21(3):193–201. https://doi.org/10.1097/MED.0000000000000062
Bislev LS, Sikjær T, Rolighed L, Rejnmark L (2015) Relationship between aldosterone and parathyroid hormone, and the effect of angiotensin and aldosterone inhibition on bone health. Clin Rev Bone Miner Metab 13(3):194–205. https://doi.org/10.1007/s12018-015-9182-0
Lenzini L et al (2019) PTH modulation by aldosterone and angiotensin II is blunted in hyperaldosteronism and rescued by adrenalectomy. J Clin Endocrinol Metab 104(9):3726–3734. https://doi.org/10.1210/jc.2019-00143
Naik V (2019) Aldosterone and parathyroid hormone: evidence for a clinically relevant relationship. J Endocrinol Thyroid Res 4(3):555637. https://doi.org/10.19080/JETR.2019.04.555637
Zia AA et al (2010) From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res. https://doi.org/10.1038/hr.2010.159
Y. Zhang and B. Feng, “Association of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis.,” Int. J. Clin. Exp. Med., vol. 8, no. 9, pp. 14625–33, 2015, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/26628945
Hattangady NG, Olala LO, Bollag WB, Rainey WE (2012) Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 350(2):151–162. https://doi.org/10.1016/j.mce.2011.07.034
The study protocol is approved from the institutional ethics committee of the General Hospital of Athens G Gennimatas, Greece, and the reporting of the study conforms to the Guidelines for Good Clinical Practice, the Declaration of Helsinki.
Consent to participate
Informed consent was obtained from all patients participating in the study.
Conflict of interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gravvanis, C., Papanastasiou, L., Glycofridi, S. et al. Hyperparathyroidism in patients with overt and mild primary aldosteronism. Hormones (2021). https://doi.org/10.1007/s42000-021-00319-w
- Primary aldosteronism
- Misdiagnosed forms